CG Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 61
- Market Cap
- $2.4B
- Website
- http://www.cgoncology.com
Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Drug: Cretostimogene GrenadenorepvecDrug: n-dodecyl-B-D-maltoside
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06567743
- Locations
- 🇺🇸
Southern Urology (Urology America), Lafayette, Louisiana, United States
🇺🇸The Conrad Pearson Clinic (Urology America), Germantown, Tennessee, United States
🇺🇸Urology Austin, PLLC (Urology America), Austin, Texas, United States
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
- Conditions
- Urothelial CarcinomaBladder CancerNon-Muscle Invasive Bladder CancerUrologic Cancer
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- CG Oncology, Inc.
- Registration Number
- NCT06443944
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- Conditions
- Urologic CancerNon Muscle Invasive Bladder CancerUrothelial CarcinomaBladder Cancer
- Interventions
- Drug: Cretostimogene GrenadenorepvecOther: n-dodecyl-B-D-maltoside
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 364
- Registration Number
- NCT06111235
- Locations
- 🇺🇸
Urology of Indiana, Greenwood, Indiana, United States
🇺🇸UT Health San Antonio, San Antonio, Texas, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
- Conditions
- High-grade Ta/ T1 Papillary Disease Bladder CancerNon Muscle Invasive Bladder Cancer
- Interventions
- Biological: Cretostimogene GrenadenorepvecOther: n-dodecyl-B-D-maltoside
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT04452591
- Locations
- 🇺🇸
Colorado Clinical Research, Lakewood, Colorado, United States
🇺🇸Urology Associates, Lone Tree, Colorado, United States
🇺🇸Urology of Indiana, Greenwood, Indiana, United States
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04387461
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Northwestern University, Tampa, Florida, United States
🇺🇸Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
- Conditions
- Bladder Cancer
- Interventions
- Biological: CG0070
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02365818
- Locations
- 🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸BCG Oncology, Phoenix, Arizona, United States
🇺🇸Arizona Institute of Urology, Tucson, Arizona, United States
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
- Conditions
- Bladder CancerHigh GradeNon Muscle Invasive
- Interventions
- Biological: oncolytic adenovirus expressing GMCSF
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- CG Oncology, Inc.
- Registration Number
- NCT02143804
- Locations
- 🇺🇸
BCG Oncology, Phoenix, Arizona, United States
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
- Conditions
- Bladder CancerCarcinoma in SituTransitional Cell CarcinomaCarcinoma in Situ Concurrent With Papillary Tumors
- Interventions
- Biological: CG0070 Adenovirus Vector
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- CG Oncology, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01438112
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸University of Chicago, Department of Surgery, Section of Urology, Chicago, Illinois, United States
🇺🇸Vanderbilt University Medical Center Department of Urologic Surgery, Nashville, Tennessee, United States